Related by context. All words. (Click for frequent words.) 68 lupus nephritis 67 liver fibrosis 66 renal disease 66 non alcoholic steatohepatitis 66 myelofibrosis 66 myeloproliferative disorders 65 familial amyloidotic polyneuropathy FAP 65 diabetes mellitus 65 refractory gout 65 myeloproliferative neoplasms 65 dyslipidemia 65 leukemia AML 65 systemic lupus erythematosus 65 NAFLD 65 fibrotic disease 64 T2DM 64 PAOD 64 heterozygous FH 64 proliferative diabetic retinopathy 64 sodium glucose cotransporter 64 myelofibrosis polycythemia vera 64 SHPT 64 hepatocellular carcinoma 64 secondary hyperparathyroidism 64 neovascular AMD 64 pheochromocytoma 64 systemic lupus erythematosus SLE 64 hyperkalemia 64 Rheumatoid Arthritis RA 64 Bucindolol 64 insulin sensitizers 64 hypercholesterolemia 63 macroalbuminuria 63 schizophrenia CIAS 63 AA amyloidosis 63 HeFH 63 Alzheimer Disease AD 63 myelodysplastic syndrome MDS 63 mRCC 63 CTAP# Capsules 63 metaglidasen 63 hypercalcemia 63 hepatic fibrosis 63 relapsed multiple myeloma 63 invasive candidiasis 63 SGLT2 63 ADPKD 63 cell lymphoma CTCL 63 diabetes mellitus T2DM 63 receptor tyrosine kinase inhibitor 63 JAK inhibitor 63 medullary thyroid cancer 63 Cetrorelix 63 Dapagliflozin 63 homozygous familial hypercholesterolemia 63 myeloproliferative diseases 63 essential thrombocythemia 63 atherosclerotic disease 63 INCB# [003] 63 Symadex 62 pulmonary arterial hypertension PAH 62 lactic acidosis 62 nonalcoholic steatohepatitis NASH 62 diabetic retinopathy 62 primary biliary cirrhosis 62 overt nephropathy 62 ISIS # 62 acute coronary syndromes 62 metastatic renal cell carcinoma 62 anterior uveitis 62 Myelodysplastic Syndrome MDS 62 progressive neurodegenerative disorder 62 hyperuricemia 62 systemic fungal infections 62 cardiac dysfunction 62 solid tumors 62 pulmonary hypertension PH 62 Amrubicin 62 darapladib 62 TREANDA 62 TTR amyloidosis 62 Enzastaurin 62 kidney urologic 62 anti fibrotic 62 vascular disrupting agent 62 acute decompensated heart 62 atacicept 62 pulmonary arterial hypertension 62 proliferator activated receptor 62 reperfusion injury 62 histone deacetylase HDAC inhibitor 62 terlipressin 62 vaso occlusive crisis 62 neurogenic orthostatic hypotension 62 diabetic gastroparesis 62 systolic hypertension 62 diabetic kidney 61 erythropoietic 61 Behcet uveitis 61 metastatic RCC 61 retinal vein occlusion 61 Lupus nephritis 61 metastatic neuroendocrine tumors 61 Azedra 61 6R BH4 61 acute coronary syndromes ACS 61 ATL# [001] 61 hyperglycaemia 61 Janus kinase 61 plasma kallikrein 61 ALN PCS 61 CYT# potent vascular disrupting 61 pan HDAC inhibitor 61 MTP inhibitor 61 Gleevec resistant 61 opioid induced constipation 61 Aurora kinase 61 Lu AA# 61 diabetic neuropathic pain 61 AEGR 61 castrate resistant prostate cancer 61 elevated triglyceride levels 61 endotoxemia 61 Mipomersen 61 atherothrombotic disease 61 cardio renal 61 cirrhosis liver failure 61 atherosclerosis 61 PRTX 61 idiopathic pulmonary fibrosis IPF 61 Neovascular AMD 61 T1DM 61 visilizumab 61 familial hypercholesterolemia 61 Hepatocellular Carcinoma HCC 61 Microplasmin 61 chronic thromboembolic pulmonary 61 heavily pretreated 61 MGUS 61 AA Amyloidosis 61 ADHF 61 renal insufficiency 61 VEGF receptor 61 peritumoral brain edema 61 tumor lysis syndrome 61 complement inhibitor eculizumab 61 HNSCC 61 AEG# 61 chronic HCV infection 61 homozygous FH 61 refractory angina 61 sJIA 61 Lixivaptan 61 riociguat 61 ALN TTR 61 hepatotoxicity 61 malignant pleural mesothelioma 61 tolvaptan 61 atherothrombosis 61 VAPRISOL 61 otelixizumab 61 JAK2 inhibitor 61 renal impairment 61 Atiprimod 61 alagebrium 61 colorectal carcinoma 61 recurrent glioblastoma multiforme 61 Myelofibrosis 61 carcinoid tumors 61 CIMZIA ™ 61 omecamtiv mecarbil 61 microalbuminuria 61 iron overload 61 arterial hypertension 61 Diabetic Macular Edema 61 MEK inhibitor 61 cardiac toxicity 61 Microalbuminuria 61 uveitis 61 Cushing Syndrome 60 lipid disorders 60 selective modulator 60 LHRH antagonists 60 renal fibrosis 60 Wet AMD 60 posaconazole 60 rFVIIa 60 gefitinib Iressa 60 MPS IVA 60 acute leukemias 60 PKC# 60 Cutaneous T 60 carcinoid 60 antidiabetic 60 mixed dyslipidemia 60 TNF Tumor Necrosis Factor 60 imatinib mesylate 60 TNF antagonist 60 humanized monoclonal antibody 60 dasatinib Sprycel ® 60 antihypertensive therapy 60 hypoxia inducible factor 60 Toxicities 60 Archexin 60 selective inhibition 60 vWD 60 hepatorenal syndrome 60 dilated cardiomyopathy DCM 60 indolent NHL 60 lomitapide 60 NAGS deficiency 60 bevacizumab Avastin ® 60 occlusive disease 60 pancreatic carcinoma 60 hypoparathyroidism 60 investigational humanized monoclonal antibody 60 hepatocellular cancer 60 hepatocellular carcinoma HCC 60 severe gastroparesis 60 Chronic Lymphocytic Leukemia 60 neuroendocrine tumors 60 Aviptadil 60 hematologic disorders 60 herpetic keratitis 60 nephropathy 60 diarrhea predominant irritable 60 Desmoteplase 60 cancer cachexia 60 HoFH 60 proteasome inhibitor 60 immunomodulatory 60 Diabetic Nephropathy 60 FLT3 60 intermittent claudication 60 PsA 60 antithrombotics 60 Factor VIIa 60 Tamibarotene 60 CCR9 antagonist 60 IL 1ß 60 hyperprolactinemia 60 delta gamma agonist 60 Pulmonary Arterial Hypertension PAH 60 fibromyalgia syndrome 60 chronic lymphocytic leukemia CLL 60 Systemic lupus erythematosus SLE 60 Tolvaptan 60 Phenoptin 60 gastrointestinal stromal tumor GIST 60 Ceflatonin 60 hyperphosphatemia 60 oral prodrug 60 leukemia ALL 60 receptor inhibitor 60 paroxysmal nocturnal hemoglobinuria 60 gastric carcinoma 60 AT1R 60 teplizumab 60 vascular inflammation 60 novel VDA molecule 60 nephrotoxicity 60 dyskinesia PD LID 60 SNT MC# 60 Diabetic nephropathy 60 either acutely decompensated 60 Epratuzumab 60 JAK1 60 hyperphenylalaninemia HPA due 60 AAT deficiency 60 Friedreich Ataxia FRDA 60 sodium thiosulfate STS 60 EGFR mutations 60 carcinoid syndrome 60 GW# [003] 60 decompensated heart failure 60 IV NSCLC 60 INS# [001] 60 hematologic malignancies 60 cachexia 60 chronic renal failure 60 EGFR inhibitors 60 TACI Ig 60 imatinib Gleevec ® 60 phase IIb clinical 60 diabetic microvascular complications 60 hypertriglyceridemia 60 disease modifying 60 dyslipidaemia 60 hyperinsulinemia 60 mycosis fungoides 60 atrophic gastritis 60 virus HCV infection 60 cardiac hypertrophy 60 RNAi therapeutic targeting 60 hypercholesterolaemia 60 VEGF inhibitors 60 receptor subtype 60 antiplatelet agent 60 cerebral vasospasm 59 relapsed refractory multiple myeloma 59 vandetanib 59 imatinib resistance 59 Epidermal Growth Factor Receptor 59 immune mediated 59 Ceflatonin R 59 NYHA Class II 59 prostate cancer CaP 59 alvespimycin 59 oxypurinol 59 familial ALS 59 delta isoform 59 debilitating autoimmune 59 Nexavar sorafenib 59 transthyretin TTR mediated amyloidosis 59 glomerulonephritis 59 Diabetic Retinopathy 59 superficial bladder cancer 59 selective agonist 59 erlotinib Tarceva ® 59 nicotinic alpha 7 59 glycated hemoglobin levels 59 rNAPc2 59 familial hypercholesterolemia FH 59 fibrosis 59 angiogenesis inhibitor 59 ATTR 59 SJIA 59 Pulmonary hypertension 59 Prehypertension 59 MGd 59 AP# [003] 59 neuroendocrine cancers 59 arterial thrombosis 59 anemias 59 mixed hyperlipidemia 59 protein tyrosine phosphatase 1B 59 bardoxolone 59 CCX# B 59 Tyrima 59 CD3 monoclonal antibody 59 Acute Myeloid Leukemia AML 59 Methylnaltrexone 59 Perifosine 59 nonalcoholic steatohepatitis 59 eltrombopag 59 JAK2 enzyme 59 FOLOTYN ® 59 ARIKACE ™ 59 Lupus Nephritis 59 Sudhir Agrawal D.Phil 59 IAP inhibitor 59 SSc 59 inducible nitric oxide synthase 59 endothelin receptor antagonists 59 chronic granulomatous disease 59 SUTENT 59 LPA1 receptor 59 tuberous sclerosis TS 59 Squalamine 59 CEQ# 59 proteinuria 59 von Willebrand disease 59 MALT lymphoma 59 INCB# [002] 59 Sezary syndrome 59 Posiphen 59 HIV HCV coinfected 59 cutaneous T 59 Safinamide 59 ulimorelin 59 chemokine receptor 59 neovascular 59 eprotirome 59 OXi# 59 anticancer agent 59 myeloid 59 Chronic Prostatitis 59 hepatitis C HCV 59 PRT# 59 HER2 overexpression 59 eculizumab 59 cMET 59 hyperammonemia 59 HQK 59 pancreatic adenocarcinoma 59 microvascular complications 59 AAT Deficiency 59 Exherin TM 59 Silodosin 59 myocardial ischemia 59 #beta HSD1 59 insulin sensitizing 59 chronic HBV infection 59 Fibrosis 59 BAY #-# 59 neurogenic 59 gastric adenocarcinoma 59 geographic atrophy 59 investigational compounds 59 hepatic encephalopathy 59 HCV infection 59 Triolex 59 leukemia CLL 59 chronic eosinophilic leukemia 59 thrombotic events 59 disease NAFLD 59 purpura ITP 59 targeted radiotherapeutic 59 cardiac contractility 59 Bortezomib 59 HCV infections 59 Omacetaxine 59 calcineurin inhibitors 59 tafamidis 59 basal cell carcinoma BCC 59 T#I mutant 59 Vaprisol 59 immuno inflammatory diseases 59 adrenal insufficiency 59 HuMax CD4 59 left ventricular dysfunction 59 pancreatic neuroendocrine tumors 59 REG1 59 ocrelizumab 59 MYDICAR ® 59 RhuDex ® 59 ATTR PN 59 5 HT6 receptor 59 elotuzumab 59 idiopathic thrombocytopenic purpura ITP 59 Pulmonary arterial hypertension 59 dexanabinol 59 diabetic neuropathy 59 salmeterol HFA MDI 59 small molecule activators 59 humanized anti 59 lung fibrosis 59 cerebral ischemia 59 refractory NSCLC 59 Angiotensin II 59 adenocarcinomas 59 Crohn disease CD 59 Natalizumab 59 Leber Hereditary Optic Neuropathy 59 EGFr 59 anti amnesic 59 JAK inhibitors 59 CBLC# 59 Alemtuzumab 59 CRVO 59 vidofludimus 59 Golimumab 59 Everolimus 59 diabetic retinopathy DR 59 gastrointestinal stromal tumors GIST 59 chemotherapy induced neutropenia 59 hypercholesterolemic patients 59 acute myelogenous leukemia AML 59 multiple myeloma MM 59 Azilect ® 59 PSN# [002] 59 Diabetes Mellitus 59 leukotriene pathway 59 Sapacitabine 59 PXD# 59 Parkinson disease PD 59 urothelial carcinoma 59 Ambrisentan 59 Prodarsan ® 59 Hypercholesterolemia 59 pseudobulbar affect PBA 59 lumiliximab 59 EGFR HER2 59 pharmacokinetic interactions 59 disease CDAD 59 Allergic Rhinitis 59 Familial Adenomatous Polyposis FAP 59 pancreatic NET 59 Nilotinib 59 metastatic malignant 59 choroidal neovascularization 58 Neulasta ® 58 angiotensin receptor blocker ARB 58 Haptoglobin 58 pericardial effusion 58 underlying vasculopathy 58 Gaucher Disease 58 familial adenomatous polyposis 58 Phase 2a Clinical Trial 58 Angioedema 58 Fx #A 58 ruboxistaurin 58 primary hyperparathyroidism 58 sorafenib Nexavar 58 erythematosus SLE 58 acute ischemic stroke 58 postoperative ileus 58 relapsing remitting multiple sclerosis 58 tiapamil 58 myeloperoxidase 58 Critical Limb Ischemia CLI 58 Tasimelteon 58 Raf MEK ERK 58 pathologic myopia 58 dopaminergic therapy 58 JAK3 58 HCV polymerase inhibitors 58 G6PD deficiency 58 acetonide FA 58 monogenic 58 macrovascular complications 58 Hereditary angioedema HAE 58 alkylating agent 58 Icatibant 58 subependymal giant cell 58 Aliskiren 58 failure ADHF 58 olmesartan 58 uPA 58 eosinophilic asthma 58 liposomal formulation 58 5 HT2A receptor 58 epithelial tumors 58 Alzheimer disease AD 58 TORISEL 58 TNFalpha 58 enzastaurin 58 chronic immune thrombocytopenic 58 motor neuron degeneration 58 Severe Primary IGFD 58 cardiovascular disorders 58 Hemophilia B 58 K ras 58 PEGylated interferon beta 1a 58 atypical hemolytic uremic syndrome 58 diabetic peripheral neuropathy 58 atherogenic dyslipidemia 58 microvascular disease 58 CYP #A# 58 ophthalmic diseases 58 tanespimycin 58 occlusion CRVO 58 K ras mutations 58 Dasatinib 58 CA4P 58 IL# PE#QQR 58 perifosine 58 Proteinuria 58 XmAb# 58 YONDELIS 58 cilengitide 58 investigational compound 58 HGS ETR1 58 systolic dysfunction 58 ischemic complications 58 Hypotension 58 thromboembolic 58 transthyretin amyloidosis 58 Traficet EN 58 inflammatory diseases 58 CTEPH 58 orally administered inhibitor 58 renal dysfunction 58 PPAR gamma agonist 58 biologic therapy 58 serum phosphate 58 INCB# [001] 58 lipid abnormalities 58 Carfilzomib 58 histone deacetylase inhibitor 58 Acute Coronary Syndrome 58 mu opioid receptor antagonist 58 E1 INT TM 58 neurological manifestations 58 TG# [003] 58 Aplidin 58 ocular hypertension 58 castration resistant prostate cancer 58 Vascular Endothelial Growth 58 severe sepsis 58 hyperglycemia 58 APOL1 58 myeloproliferative 58 invasive fungal infections 58 axitinib 58 phase IIb trial 58 mTOR mammalian target 58 COU AA 58 mertansine 58 metastatic renal cell 58 TRO# 58 JAK2 58 chronic myeloid leukemia CML 58 DFMO 58 non metastatic osteosarcoma 58 P#X# 58 Elesclomol 58 atypical Hemolytic Uremic Syndrome 58 neurodegenerative 58 metastatic GIST 58 Meets Primary Endpoint 58 Exelixis XL# 58 neurodegenerative disease 58 nosocomial pneumonia 58 PKC beta 58 diabetic macular edema 58 antithrombotic 58 pancreatic alpha 58 heparin induced thrombocytopenia 58 TCF#L# 58 sunitinib Sutent 58 macrovascular disease 58 receptor antagonist 58 PF # [001] 58 Panzem R 58 macular edema 58 ADAMTS# 58 TGF β 58 gastrointestinal stromal tumor 58 anticancer therapy 58 antisense oligonucleotide 58 paroxysmal AF 58 haematologic 58 Eltrombopag 58 coagulation cascade 58 hematological malignancies 58 β blockers 58 blepharitis 58 biliary tract cancer 58 Enzyme Replacement Therapy 58 peripheral arterial disease 58 interleukin IL -# 58 chronic myocardial ischemia 58 Idiopathic pulmonary fibrosis 58 Insulin resistance 58 chronic kidney 58 Ischemic 58 synthetic retinoid 58 gouty arthritis 58 demyelination 58 NSCLC 58 cytopenias 58 LymphoStat B 58 renal cell carcinoma 58 Unit Dose Budesonide 58 renin inhibitors 58 PDGF receptor 58 hypereosinophilic syndrome 58 Amplimexon 58 receptor agonist 58 noninfectious uveitis 58 CD# monoclonal antibody 58 systemic scleroderma 58 pediatric Crohn disease 58 onset diabetes mellitus 58 neuropathic pain 58 #ME# 58 neuropathic pain metabolic diseases 58 refractory CTCL 58 Aortic stenosis 58 Hepatitis C virus HCV 58 EGFR tyrosine kinase inhibitors 58 ATL/TV# 58 rheumatoid arthritis psoriatic arthritis 58 Cethromycin 58 Candesartan 58 hyperlipidemia 58 GABITRIL 58 B CLL 58 cytopenia 58 inhibitor RG# 58 SPP# [001] 58 induce orthostatic hypotension 58 SCCHN 58 Glucocorticoids 58 receptor agonists 58 gastrointestinal GI motility disorders 58 proliferative retinopathy 58 nucleoside analogues 58 degenerative retinal diseases 58 lymphoma CTCL 58 V#F mutation 58 antithrombotic agents 58 mGluR2 NAM 58 refractory acute myeloid 58 phase IIa clinical 58 dirucotide 58 Alfimeprase 58 Hepatic 58 opioid induced bowel dysfunction 58 hepatocellular 58 malignant neoplasms 58 ENMD # 58 seropositive patients 58 Bendavia 58 Aflibercept 58 HCV protease inhibitors 57 renal toxicity 57 A1PI 57 CDK inhibitor 57 Vascugel 57 cytomegalovirus infection 57 PEG SN# 57 neurodegenerative disorder 57 vitreoretinal disorders 57 acute myeloid leukemia AML 57 APOPTONE 57 disease progression 57 acadesine 57 dual PPAR peroxisome 57 HDACi 57 CYT# 57 PDGFR 57 Overactive Bladder 57 NF1 57 Chronic Kidney Disease 57 dyslipidemic 57 PD LID 57 Ranolazine 57 Tyrosine Kinase Inhibitor 57 pathogenetic 57 HBeAg negative 57 mitochondrial toxicity 57 VIPR2 57 postoperative atrial fibrillation 57 Annamycin 57 Chronic Lymphocytic Leukemia CLL 57 Nuvion 57 MULTAQ 57 HuLuc# 57 Leber Congenital Amaurosis LCA 57 ischemic cardiomyopathy 57 Cyclosporine 57 Lubiprostone 57 Myelodysplastic syndromes MDS 57 relapsed leukemia 57 rheumatic diseases 57 tipifarnib 57 AQ4N 57 oral candidiasis 57 gastric cancers 57 Cinquil 57 antisense drug 57 rheumatic disease 57 gastric carcinogenesis 57 GvHD 57 ALN TTR# 57 immune modulation 57 natriuretic peptide 57 Ulcerative Colitis 57 critical limb ischemia 57 catheter occlusion 57 Azixa 57 muraglitazar 57 cytostatic 57 Non Alcoholic Fatty 57 urate lowering 57 tocilizumab 57 choroidal neovascularization CNV 57 autoimmune diseases 57 Systemic Lupus Erythematosus 57 endothelin receptor 57 Viprinex 57 juvenile idiopathic arthritis JIA 57 antiarrhythmic drug 57 Pulmonary Arterial Hypertension 57 Gleevec imatinib mesylate 57 Vernakalant 57 anti CD3 antibody 57 LY# [002] 57 PNP inhibitor 57 direct thrombin inhibitors 57 hematopoietic cancers 57 Severe Sepsis 57 thromboembolic events 57 imatinib resistant 57 Peripheral Artery Disease 57 Bevacizumab 57 Fibrillex TM 57 haematopoietic 57 IPL# 57 thalidomide Thalomid 57 IL 1beta 57 Trandolapril 57 oncology indications 57 MELAS 57 multi kinase inhibitor 57 IFN α 57 TTR gene 57 methylnaltrexone 57 chronic myeloid 57 liver metastases 57 vascular disease 57 SAR# [004] 57 anti angiogenic therapy 57 autoantibody positive 57 GSK # 57 aortic valve stenosis 57 bucindolol 57 bexarotene 57 rheumatoid arthritis RA 57 alcoholic fatty liver 57 hyperparathyroidism 57 skeletal metastases 57 hypertension 57 BIBW 57 EOquin 57 Vidofludimus 57 malignant lymphomas 57 medullary thyroid carcinoma 57 Diabetic neuropathy 57 pancreatic insufficiency 57 CIMZIA TM 57 neoplastic 57 insulin sensitizer 57 signal transduction inhibitor 57 neuropsychiatric disorders 57 Endothelial dysfunction 57 aHUS 57 serum urate levels 57 T2D 57 maribavir 57 cerebrospinal fluid CSF 57 drug ISA# 57 Serdaxin 57 huC# DM4 57 atherogenesis 57 forodesine 57 relapsing remitting MS RRMS 57 soluble tumor necrosis 57 MEK inhibitors 57 Pseudomonas aeruginosa infections 57 resistant hypertension 57 daptomycin 57 ISTODAX 57 Advanced Renal Cell 57 renal anemia 57 natriuretic peptides 57 NQO1 57 Malignant Melanoma 57 cell lymphomas 57 LymphoStat B belimumab 57 BENLYSTA TM 57 Carcinoid tumors 57 vWF 57 TELINTRA 57 advanced hepatocellular carcinoma 57 luteinizing hormone releasing 57 Chronic Myeloid Leukemia CML 57 anticancer compound 57 Critical limb ischemia 57 lymphomas 57 Firazyr 57 Zollinger Ellison Syndrome 57 ara C 57 Sym# 57 peptide BNP 57 metastatic melanoma 57 demethylating agents 57 PTP 1B 57 colorectal cancer CRC 57 glucagon receptor 57 PTLD 57 tumor necrosis 57 cell lymphoma ALCL 57 5 HT2B receptor 57 Xyfid TM 57 Thrombocytopenia 57 cyclin E 57 GRNCM1 57 induce apoptosis 57 hematopoietic 57 adult chronic ITP 57 primary hypercholesterolemia 57 Cachexia 57 refractory AML 57 valvular disease 57 LHON 57 isoenzyme 57 cell adhesion molecule 57 PS# [001] 57 polycythemia vera PV 57 postoperative ileus POI 57 fosbretabulin 57 HCV 57 idarubicin 57 systemic inflammation 57 AKT inhibitor 57 Benign Prostatic Hyperplasia 57 gastrointestinal stromal tumors 57 antiarrhythmic 57 metastatic colorectal 57 EndoTAG TM -1 57 HGS# 57 post herpetic neuralgia PHN 57 dexpramipexole 57 1 diabetes T1D 57 HSP# inhibitor 57 serine protease 57 Clusterin 57 pathophysiologic 57 LY# [003] 57 refractory metastatic colorectal cancer 57 tamibarotene 57 Belimumab 57 lung metastasis 57 cognitive dysfunction 57 Catena ® 57 prostate carcinoma 57 vascular permeability 57 Pirfenidone 57 cIAI 57 ansamycin 57 Tumor Necrosis Factor 57 EXJADE 57 trial evaluating PRX# 57 IFN beta 57 TMEM#B 57 Torisel 57 Glioblastoma Multiforme 57 CNS disorders 57 Vandetanib 57 endothelial dysfunction 57 somatostatin analogue 57 chronic myelogenous leukemia CML 57 Etanercept 57 pertuzumab 57 hypercalcaemia 57 thromboembolism 57 Fc fusion protein 57 Octreolin 57 mCRC 57 Hodgkin lymphoma HL 57 Ozarelix 57 Janus Kinase 57 cobiprostone 57 MGCD# [001] 57 aripiprazole Abilify 57 Eculizumab 57 basiliximab 57 diabetes mellitus DM 57 angiotensin receptor blockers 57 recurrent glioblastoma 57 HbF 57 thromboembolic complications 57 interferon IFN 57 post operative ileus 57 Decitabine 57 VA# [002] 57 metastatic cancers 57 antihypertensive drugs 57 endothelial activation 57 allergic inflammation 57 stage IIIB 57 Syncria R 57 2 diabetes T2D 57 c MET 57 TKM ApoB 57 Ofatumumab 57 progressive dyspnea 57 beta interferons 57 Cannabinor 57 pediatric acute lymphoblastic 57 alvimopan 57 targeting CD# 57 Cardiotoxicity 57 Aclidinium 57 erythematosus 57 allograft rejection 57 Uricase PEG 57 hyperphosphorylation 57 PPAR gamma agonists 57 hypervascular tumors 57 FOLOTYN 57 Cleviprex TM clevidipine 57 lymphoid malignancies 57 Nanobody 57 Hp2 2 57 Treg cell 57 RDEA# 57 dasatinib Sprycel 57 Zolinza 57 Papillary 57 Xanafide 57 polymerase inhibitor 57 azacitidine 57 IMiDs ® 57 PARP inhibitors 57 immunodeficiency 57 APTIVUS r 57 malignancies 57 partial agonist 57 neurotrophic 57 KIACTA ™ 57 Cholangiocarcinoma 57 PI3K/Akt pathway inhibitor 57 induced macular edema 57 TMS Therapy 57 talactoferrin